Placeholder Banner

BIO Statement on New PDUFA Package

May 4, 2022
Media Contact

The House Energy & Commerce Committee today unveiled a new package for the Prescription Drug User Fee Act (PDUFA). After the release, BIO’s Chief Science Officer, Cartier Esham, made the following remarks:

 "For more than thirty years, the FDA user fee programs have shown tremendous results in delivering life-saving medicines to patients who urgently need them.  These agreements between the industry and FDA include important provisions to improve the use of real-world evidence, modernize, streamline, and diversify clinical trials, and ensure that the Agency has the resources necessary to support the world-leading innovation our companies bring to patients every day.  

 "While we are still analyzing the bill, we are pleased to see bipartisan support from the Energy & Commerce Committee for these critical public health programs.  We are further encouraged that the Committee recognizes the importance of a timely reauthorization and has worked together to develop a bill that will continue the shared goal of transforming and improving patients’ lives for years to come.  We look forward to working with the Committee on in the coming weeks to achieve that goal."

Discover More
The Biotechnology Innovation Organization (BIO) is pleased to announce the election of its new Executive Committee directors for the 2022-2023 term. BIO’s Board elections took place Monday, June 13 during the 2022 BIO International Convention…
The third annual report that examines diversity, equity, and inclusion (DEI) in the biotechnology industry launched today at the 2022 BIO International Convention. The report, “Measuring Diversity in the Biotech Industry: Tracking Progress in Small…
The licensing of university and nonprofit research has made a significant contribution to US gross domestic product (GDP), industrial gross output, and jobs over the last 25 years and underscores the importance of basic and applied research to the…